# Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer

> **NCT05943041** · PHASE1 · COMPLETED · sponsor: **GILongevity** · enrollment: 9 (actual)

## Conditions studied

- Solid Tumor
- Colorectal Cancer
- Sigmoid Colon Cancer
- Rectosigmoid Junction Cancer
- Cancer
- Rectal Cancer

## Interventions

- **DRUG:** GB104(Level 1)
- **DRUG:** GB104(Level 2)
- **DRUG:** GB104(Level 3)

## Key facts

- **NCT ID:** NCT05943041
- **Lead sponsor:** GILongevity
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-28
- **Primary completion:** 2023-12-22
- **Final completion:** 2023-12-22
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05943041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05943041, "Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05943041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*